NCT07230600 AD-SVF Therapy for Refractory Endometrial Infertility
| NCT ID | NCT07230600 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Condition | Endometrium; Atrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2025-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to initially explore the efficacy of adipose-derived stromal vascular fraction (AD-SVF) therapy in the treatment of refractory endometrial infertility.
Eligibility Criteria
Inclusion Criteria: 1. refractory thin endometrium (endometrial thickness \< 6 mm on the day of ovulation or the day of endometrial transformation during a hormone replacement cycle) and/or moderate to severe intrauterine adhesion； 2. Inability to undergo autologous bone marrow stem cells-scaffold (BMSC) transplantation due to failed bone marrow aspiration, or lack of significant effect following the BMSC treatment; 3. with fertility intentions; 4. normal ovarian function or availability of cryopreserved embryos; 5. 18kg/m\^2 \< body mass index (BMI) \< 30kg/m\^2; Exclusion Criteria: 1. Chromosomal karyotype abnormalities in one spouse; 2. Severe endometriosis, uterine fibroids affecting the uterine cavity morphology, or uterine malformations; 3. Abnormalities in coagulation function, hepatic or renal function, or other underlying conditions deemed by the investigator to potentially impact the study's progression (uncontrolled hypertension, diabetes, autoimmune diseases, etc.); 4. Contraindications for pregnancy; 5. Contraindications for hormonal cycle therapy; 6. History of pelvic tumors; 7. Simultaneous participation in other clinical studies.
Contact & Investigator
Yali Hu
PRINCIPAL INVESTIGATOR
The Affiliated Drum Tower Hospital of Nanjing University
Frequently Asked Questions
Who can join the NCT07230600 clinical trial?
This trial is open to female participants only, aged 22 Years or older, up to 45 Years, studying Endometrium; Atrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07230600 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07230600 currently recruiting?
Yes, NCT07230600 is actively recruiting participants. Contact the research team at glyyhuyali@163.com for enrollment information.
Where is the NCT07230600 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07230600 clinical trial?
NCT07230600 is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. The principal investigator is Yali Hu at The Affiliated Drum Tower Hospital of Nanjing University. The trial plans to enroll 10 participants.